AzTrials
AzTrials

Relapsing Remitting Multiple SclerosisPhase 4TOPAZNCT02255656

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409

A Phase 4 study testing alemtuzumab GZ402673 in people with Relapsing Remitting Multiple Sclerosis, run by Genzyme, a Sanofi Company at 131 sites in 19 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Primary Objective: To evaluate long-term safety of alemtuzumab. Secondary Objectives: To evaluate long term efficacy of alemtuzumab. To evaluate the safety profile of participants who received other Disease Modifying Treatment (DMT) following alemtuzumab treatment. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Relapsing Remitting Multiple Sclerosis
What is being tested?
alemtuzumab GZ402673
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,062 participants
Where
131 sitesin 19 countries
Study dates
7 Jan 2015to 15 Jul 2020
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Participant had completed at least 48 months of the Extension Study CAMMS03409. Signed written informed consent form.

Who cannot join

  • Participant participating in another investigational interventional study.
  • The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Trial locations and contacts

131 sites in 19 countries.

131 sites in 19 countries

United States52 sites
  • Investigational Site Number 1014

    Albuquerque, New Mexico, 87131

  • Investigational Site Number 1097

    Allentown, Pennsylvania, 18103

  • Investigational Site Number 1025

    Ann Arbor, Michigan, 48105-2945

  • Investigational Site Number 1040

    Berkeley, California, 94705

  • Investigational Site Number 1095

    Chapel Hill, North Carolina, 27599

  • Investigational Site Number 1035

    Cleveland, Ohio, 44195

  • Investigational Site Number 1163

    Cordova, Tennessee, 38018

  • Investigational Site Number 1086

    Cullman, Alabama, 00000

  • Investigational Site Number 1017

    Des Moines, Iowa, 50314

  • Investigational Site Number 1020

    Detroit, Michigan, 48201

  • Investigational Site Number 1027

    Fort Collins, Colorado, 80528

  • Investigational Site Number 1001

    Fort Wayne, Indiana, 46845

  • Investigational Site Number 1055

    Franklin, Tennessee, 37064

  • Investigational Site Number 1152

    Fullerton, California, 92835

  • Investigational Site Number 1018

    Houston, Texas, 77030

  • Investigational Site Number 1024

    Indianapolis, Indiana, 46202

  • Investigational Site Number 1078

    Jacksonville, Florida, 32209

  • Investigational Site Number 1022

    Kansas City, Kansas, 66160

  • Investigational Site Number 1084

    Kansas City, Missouri, 64111

  • Investigational Site Number 1009

    Knoxville, Tennessee, 37922

  • Investigational Site Number 1083

    Lenexa, Kansas, 66214

  • Investigational Site Number 1039

    Lexington, Kentucky, 40513

  • Investigational Site Number 1021

    Louisville, Kentucky, 40202

  • Investigational Site Number 1059

    Maitland, Florida, 32751

  • Investigational Site Number 1081

    Mineola, New York, 11501

  • Investigational Site Number 1042

    Nashville, Tennessee, 37215

  • Investigational Site Number 1026

    New York, New York, 10029

  • Investigational Site Number 1008

    Northbrook, Illinois, 60062

  • Investigational Site Number 1067

    Oklahoma City, Oklahoma, 73104

  • Investigational Site Number 1093

    Pasadena, California, 91105

  • Investigational Site Number 1160

    Patchogue, New York, 11772

  • Investigational Site Number 1031

    Phoenix, Arizona, 85013

  • Investigational Site Number 1171

    Phoenix, Arizona, 85018

  • Investigational Site Number 1057

    Providence, Rhode Island, 02905

  • Investigational Site Number 1015

    Rochester, New York, 14642

  • Investigational Site Number 1002

    Round Rock, Texas, 78681

  • Investigational Site Number 1046

    San Antonio, Texas

  • Investigational Site Number 1173

    Sarasota, Florida, 34239

  • Investigational Site Number 1068

    Seattle, Washington, 98122

  • Investigational Site Number 1092

    St Louis, Missouri, 63131

  • Investigational Site Number 1034

    Sunrise, Florida, 33351

  • Investigational Site Number 1053

    Syracuse, New York, 13202

  • Investigational Site Number 1005

    Tampa, Florida, 33609

  • Investigational Site Number 1049

    Tampa, Florida, 33612

  • Investigational Site Number 1073

    Teaneck, New Jersey, 07666

  • Investigational Site Number 1054

    Traverse City, Michigan, 49684

  • Investigational Site Number 1090

    Tucson, Arizona, 85704

  • Investigational Site Number 1058

    Uniontown, Ohio, 44685

  • Investigational Site Number 1037

    Vienna, Virginia, 22182

  • Investigational Site Number 1061

    Wellesley, Massachusetts, 02481

  • Investigational Site Number 1082

    Winston-Salem, North Carolina, 27103

  • Investigational Site Number 1028

    Worcester, Massachusetts, 01655

Other trials in United States

Russia11 sites
  • Investigational Site Number 6009

    Kazan', 420097

  • Investigational Site Number 6001

    Moscow, 1217015

  • Investigational Site Number 6005

    Moscow, 1217015

  • Investigational Site Number 6003

    Moscow

  • Investigational Site Number 6006

    Nizhny Novgorod

  • Investigational Site Number 6010

    Pyatigorsk

  • Investigational Site Number 6002

    Saint Petersburg

  • Investigational Site Number 6004

    Saint Petersburg

  • Investigational Site Number 6008

    Saint Petersburg

  • Investigational Site Number 6013

    Samara

  • Investigational Site Number 6016

    Ufa

Other trials in Russia

Australia9 sites
  • Investigational Site Number 2013

    Auchenflower, 4066

  • Investigational Site Number 2001

    Heidelberg, 3084

  • Investigational Site Number 2011

    Hobart, 7000

  • Investigational Site Number 2012

    Kogarah, 2217

  • Investigational Site Number 2003

    Melbourne, 3065

  • Investigational Site Number 2002

    Parkville, 3050

  • Investigational Site Number 2005

    Southport, 4215

  • Investigational Site Number 2009

    Sydney

  • Investigational Site Number 2006

    Westmead, 2145

Other trials in Australia

Germany9 sites
  • Investigational Site Number 4602

    Berlin, 13347

  • Investigational Site Number 4607

    Dresden, 01307

  • Investigational Site Number 4634

    Frankfurt am Main, 60590

  • Investigational Site Number 4622

    Hamburg, 22307

  • Investigational Site Number 4605

    Hanover, 30625

  • Investigational Site Number 4609

    Hennigsdorf, 16761

  • Investigational Site Number 4608

    München, 81675

  • Investigational Site Number 4610

    Rostock, 18147

  • Investigational Site Number 4613

    Wermsdorf, 04779

Other trials in Germany

Canada7 sites
  • Investigational Site Number 1102

    Calgary, T2N 2T9

  • Investigational Site Number 1105

    Gatineau, J8Y1W2

  • Investigational Site Number 1104

    Greenfield Park, J4V2J2

  • Investigational Site Number 1109

    Kingston, K7L2V7

  • Investigational Site Number 1110

    London, N6A5A5

  • Investigational Site Number 1101

    Ottawa, K1H8L6

  • Investigational Site Number 1106

    Vancouver, V6T1Z3

Other trials in Canada

United Kingdom6 sites
  • Investigational Site Number 4004

    Bristol, BS105NB

  • Investigational Site Number 4001

    Cambridge, CB50QQ

  • Investigational Site Number 4005

    Cardiff, CF44XN

  • Investigational Site Number 4006

    London, E12AT

  • Investigational Site Number 4008

    Salford, M68HD

  • Investigational Site Number 4007

    Sheffield, S102JF

Other trials in United Kingdom

Poland5 sites
  • Investigational Site Number 4902

    Krakow, 31-505

  • Investigational Site Number 4901

    Lodz, 90-324

  • Investigational Site Number 4903

    Lublin, 20-090

  • Investigational Site Number 4904

    Poznan, 60-355

  • Investigational Site Number 4905

    Warsaw, 02-957

Other trials in Poland

Brazil4 sites
  • Investigational Site Number 3006

    Porto Alegre, 90110000

  • Investigational Site Number 3002

    Recife, 52010-040

  • Investigational Site Number 3001

    São Paulo, 01221-000

  • Investigational Site Number 3003

    São Paulo, 05403-000

Other trials in Brazil

Czechia4 sites
  • Investigational Site Number 4803

    Brno, 65691

  • Investigational Site Number 4804

    Hradec Králové, 50005

  • Investigational Site Number 4801

    Prague, 12808

  • Investigational Site Number 4802

    Teplice, 41501

Other trials in Czechia

Italy4 sites
  • Investigational Site Number 4112

    Cagliari, 09126

  • Investigational Site Number 4102

    Gallarate (VA), 21013

  • Investigational Site Number 4106

    Orbassano (TO), 10043

  • Investigational Site Number 4110

    Roma, 00189

Other trials in Italy

Spain4 sites
  • Investigational Site Number 4301

    Barcelona, 08035

  • Investigational Site Number 4303

    Madrid, 28040

  • Investigational Site Number 4305

    Málaga, 29010

  • Investigational Site Number 4304

    Seville, 41071

Other trials in Spain

Belgium3 sites
  • Investigational Site Number 5005

    Brussels, 1200

  • Investigational Site Number 5004

    Esneux, 4130

  • Investigational Site Number 5001

    Leuven, 3000

Other trials in Belgium

Ukraine3 sites
  • Investigational Site Number 6102

    Kharkiv

  • Investigational Site Number 6104

    Kiev

  • Investigational Site Number 6103

    Lviv

Other trials in Ukraine

Denmark2 sites
  • Investigational Site Number 5302

    Aarhus N, 8200

  • Investigational Site Number 5301

    København Ø, 2100

Other trials in Denmark

Israel2 sites
  • Investigational Site Number 5501

    Ramat Gan, 52621

  • Investigational Site Number 5505

    Tel Aviv

Other trials in Israel

Mexico2 sites
  • Investigational Site Number 3105

    Chihuahua City, 31203

  • Investigational Site Number 3102

    México, 14260

Other trials in Mexico

Sweden2 sites
  • Investigational Site Number 4701

    Gothenburg, 41345

  • Investigational Site Number 4702

    Umeå, 90185

Other trials in Sweden

Argentina1 site
  • Investigational Site Number 03208

    CABA, C1061ABD

Other trials in Argentina

Netherlands1 site
  • Investigational Site Number 4202

    Sittard-Geleen, 6162BG

Other trials in Netherlands

About this study

Official title: A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409)

Primary Objective:

To evaluate long-term safety of alemtuzumab.

Secondary Objectives:

  • To evaluate long term efficacy of alemtuzumab.
  • To evaluate the safety profile of participants who received other Disease Modifying Treatment (DMT) following alemtuzumab treatment.
  • To evaluate participant-reported Quality of Life (QoL) outcomes and health resource utilization of participant who received alemtuzumab.
  • To evaluate as needed re-treatment with alemtuzumab and other DMTs.
Read the detailed description

The total duration per participants was up to 5.6 years.

As per Study Investigator discretion, participants can be treated with additional courses of alemtuzumab or any commercialized DMTs.

All participants who completed CAMMS03409 were allowed into the study, which might include specific vulnerable populations. If the investigator decided to treat a participant with a course of alemtuzumab, appropriate cautionary measures were applied as indicated in the approved labelling, or, in ex-European Union countries where Lemtrada was not approved, according to the investigator's brochure.

Being tested
alemtuzumab GZ402673
Medical subject headings
Multiple Sclerosis, Relapsing-Remitting

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • alemtuzumab GZ402673Drug

    Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous

Study groups in NCT02255656
Study groupRoleWhat they receive
AlemtuzumabExperimentalAll Participants who completed the study CAMMS03409 (extension study of CAMMS223 [NCT00050778], CAMMS323 [NCT00530348], or CAMMS324 [NCT00548405]) and received alemtuzumab within 48 months prior to enrollment were included in this LPS13649 study. Participants received alemtuzumab, intravenous infusion of 12 milligram per day (mg/day) for 3 consecutive days, at the study investigators' discretion; and at least 12 months after the prior treatment course in the current study (LPS13649).
Receives: Drug: alemtuzumab GZ402673

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs)

    An Adverse Event (AE) was any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily had to have causal relationship with treatment. TEAEs were defined as AEs that developed/worsened during the 'treatment period (time from Baseline until the end of the study LPS13649 [i.e. up to a maximum of 5.6 years]). Serious adverse events (SAEs) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.

    Measured: From Baseline until the end of the study (up to a maximum duration of 5.6 years)

  2. Number of Participants With Infusion-Associated Reactions (IAR)

    Infusion-associated reactions (IAR) was defined as any adverse event occurring during and within 24 hours of alemtuzumab infusion.

    Measured: Within 24 hours of any alemtuzumab infusion

  3. Number of Participants With Adverse Events of Special Interest (AESI)

    Adverse events of special interest included the following: hypersensitivity or anaphylaxis; pregnancy of a woman entered in the study; symptomatic overdose (serious or non-serious) with investigational medicinal Product (IMP); increase in alanine transaminase (ALT); autoimmune mediated conditions; hemophagocytic lymphohistiocytosis; progressive multifocal leukoencephalopathy; temporally associated AEs; serious infections; malignancy; and pneumonitis.

    Measured: From Baseline until the end of the study (up to a maximum duration of 5.6 years)

  4. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities

    Criteria for potentially clinically significant laboratory abnormalities included:

    • Hemoglobin (Hb): less than or equal to (<=)115 grams per liter (g/L)(Male [M]), <= 95 g/L (Female[ F]); greater than or equal to (>=)185 g/L (M), >= 165 g/L (F); Decrease From Baseline (DFB) >= 20 g/L.
    • Hematocrit: <= 0.37 volume/volume (v/v) (M); <= 0.32 v/v (F); >= 0.55 v/v (M); >= 0.5 v/v (F).
    • Red Blood Cells (RBCs): >=6 *10^12/L.
    • Platelets: <100 *10^9/L; >=700 *10^9/L. As pre-specified, data collection and analysis for this outcome measure was done on the overall population along with 2 subgroups (DAT and IAT).

    Measured: From Baseline until the end of the study (up to a maximum duration of 5.6 years)

Secondary outcomes (22)
  1. Annualized Relapse Rate

    Relapse was defined as new neurological symptoms or worsening of previous neurological symptoms with an objective change on neurological examination. Annualized relapse rate was obtained from the total number of confirmed relapses that occurred during the treatment follow up time of all participants divided by the total years of follow-up for all participants. The annualized relapse rate was estimated using a negative binomial model with robust variance estimation.

    Measured: Up to a maximum duration of 5.6 years

  2. Proportion of Participants Who Were Relapse Free

    Relapse was defined as new neurological symptoms or worsening of previous neurological symptoms with an objective change on neurological examination. The proportion of participants who were relapse free (without event) were estimated using the Kaplan-Meier method.

    Measured: Up to a maximum duration of 5.6 years

  3. Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Month 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60

    EDSS is an ordinal scale in half-point increments that qualifies disability in participants with multiple sclerosis (MS). It consists of 8 ordinal rating scales assessing seven functional systems (pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, cerebral, and other). EDSS total score ranges from 0 (normal neurological examination) to 10 (death due to MS), where higher scores indicated worst outcomes.

    Measured: Baseline (Month 0 of LPS13649), Month 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60

  4. Brain Magnetic Resonance Imaging (MRI) Assessment: Number of Gadolinium Enhancing (Gd-enhancing) Lesions Per MRI Scan

    Number of Gd-enhancing lesions per scan was defined as the total number of Gd-enhancing lesions that occurred during the treatment period divided by the total number of scans performed during the treatment period. The adjusted cumulative count of lesions was estimated by a repeated negative binomial regression with generalized estimating equation (GEE) adjusted for analysis groups and geographic region as covariates.

    Measured: Up to a maximum duration of 5.6 years

  5. Brain Magnetic Resonance Imaging (MRI) Assessment: Number of New or Enlarged T2 Lesions Per MRI Scan

    Number of new or enlarged T2 lesions per scan was defined as the total number of new or enlarged T2 lesion that occurred during treatment period divided by the total number of scans performed during treatment period. The adjusted cumulative count of lesions was estimated by a repeated negative binomial regression with GEE adjusted for analysis groups and geographic region as covariates.

    Measured: Up to a maximum duration of 5.6 years

  6. Brain Magnetic Resonance Imaging (MRI) Assessment: Number of New T1 (and New Hypointense T1) Lesions Per MRI Scan

    Number of new T1 lesions per scan was defined as the total number of new T1 lesion (and New Hypointense T1) that occurred during treatment period divided by the total number of scans performed during treatment period.The adjusted cumulative count of lesions was estimated by a repeated negative binomial regression with GEE adjusted for analysis groups and geographic region as covariates.

    Measured: Up to a maximum duration of 5.6 years

  7. Brain Magnetic Resonance Imaging (MRI) Assessment: Percent Change From Baseline in Volume of T1 Lesions at Months 12, 24, 36, 48, and 60

    The total lesion volume (T1 lesions) was measured by MRI scan.

    Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60

  8. Brain Magnetic Resonance Imaging (MRI) Assessment: Percent Change From Baseline in Volume of T2 Lesions at Months 12, 24, 36, 48, and 60

    The total lesion volume (T2 lesions) was measured by MRI scan.

    Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60

  9. Brain Magnetic Resonance Imaging (MRI) Assessment: Percent Change From Baseline in Brain Parenchymal Fraction (BPF) at Month 12, 24, 36, 48, and 60

    The brain parenchymal fraction was measured by MRI scan.

    Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60

  10. Change From Baseline in Self-reported Quality of Life (QoL) as Assessed by the Medical Outcome Study (MOS) 36-Item Short-Form Health Survey (SF-36): Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores at Month 12, 24, 36, 48, and 60

    The MOS SF-36 is an extensively validated and widely used measure of QoL that assesses participants' perceptions of health status and its impact on their lives. It consisted of 36 items organized into 8 scales (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health). Two summary measures of physical and mental health, the PCS and MCS, respectively, were derived from scale aggregates, and were reported in this outcome measure. The score range for each of these 2 summary scores was from 0 (worst) to 100 (best), higher scores indicated better QoL.

    Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60

  11. Change From Baseline in Functional Assessment of Multiple Sclerosis (FAMS) Score at Month 12, 24, 36, 48, and 60

    The FAMS is a self-reported multidimensional index comprising a total of 58 items on 7 subscales: mobility (7 items); symptoms (7 items); emotional well-being (7 items); general contentment (7 items); thinking and fatigue (9 items); family/social well-being (7 items); and additional concerns (14 items, these are not scored). Each item (except those for "additional concerns") was rated on a 5-point scale of 0 (lower quality of life) to 4 (higher quality of life). Total FAMS score was the sum of 44 scored items, which ranged from 0 (poor) to 176 (best), with higher numbers reflecting a higher quality of life.

    Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60

  12. Change From Baseline in European Quality of Life -5 Dimension (EQ-5D) Score: Utility Scores at Month 12, 24, 36, 48, and 60

    The EQ-5D is a generic, standardized instrument that provides a simple, descriptive profile and a single index value for health status used in the clinical and economic evaluation of health care as well as in population health surveys. The EQ-5D comprises 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension measured on 3 levels: some, moderate, and extreme problems. The 5 dimensional 3-level systems was converted into single index utility score ranges from 0 to 100, where 100=best health state; and 0=worst health state; higher scores indicated better outcome.

    Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60

  13. Change From Baseline in EQ-5D Visual Analogue Scale (VAS) Scores at Month 12, 24, 36, 48, and 60

    EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0 to 100), where 0=worst imaginable health state to 100=best imaginable health state, and higher score indicated better outcome.

    Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60

  14. Modified Healthcare Resource Utilization Questionnaire (HRUQ): Number of Participants Who Reported Change in Employment Situation, Availing of Sick Leaves, Admissions and Stays in Hospital, Rehabilitation Centers or Nursing Homes Due to Multiple Sclerosis

    Participants use of healthcare resources, non-medical resources, and informal care as well as their work capacity was assessed at scheduled study visits using a modified questionnaire (HRUQ) designed to evaluate the economic impact of MS. Questionnaire addresses the following content areas: employment situation and changes in employment situation due to MS;sick leaves,admissions and stays in hospital, rehabilitation centers, or nursing homes; typical MS-related investments (eg, stair and bed lift, ramps,rails) and devices (eg,walking aids,wheelchairs); assistance by community or social services (e.g. home nurse, transportation), or help from family or friends. Each question requires a binary answer (yes/no). Number of participants who reported "Yes" as an answer to "employment situation change; had sick leaves; had hospital admission; had spent time in rehabilitation center and had spent time in a nursing home or a similar institution" questions were reported in this outcome measure.

    Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60

  15. Modified HRUQ: Number of Participants Who Reported Other Changes/Changes in Lifestyle Due to Multiple Sclerosis

    Participants use of healthcare resources, non-medical resources, and informal care as well as their work capacity was assessed at scheduled study visits using a modified questionnaire (HRUQ) designed to evaluate the economic impact of MS.Questionnaire addresses following content areas: employment situation and changes in employment situation due to MS; admissions and stays in hospital, rehabilitation centers, or nursing homes; typical MS-related investments(e.g.stair and bed lift,ramps,rails) and devices(e.g.walking aids,wheelchairs);assistance by community or social services(e.g.home nurse, transportation), or help from family or friends. Each question requires a binary answer (yes/no). Number of participants who reported other changes/changes in lifestyle due to MS, i.e."Yes" as an answer to "had made changes to your house, apartment, car or did you require any special equipment or aids; assistance required; other assistance required" questions were reported in this outcome measure.

    Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60

  16. Health Related Productivity Questionnaire (HRPQ): Number of Participants Reporting Current Employment Status (Part Time/Full Time/Not Employed) Due to Multiple Sclerosis

    Participants use of healthcare resources, non-medical resources, and informal care as well as their work capacity was assessed at scheduled study visits using a modified questionnaire (HRPQ) designed to evaluate the economic impact of MS. The questionnaire addresses the following content area: participant reported data regarding employment status, work productivity, impact on household chores due to MS. Current employment status of participants (i.e. Part Time/Full Time/Not Employed) was reported in this outcome measure.

    Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60

  17. HRPQ: Total Scheduled Working Hours and Number of Hours Missed From Work Due to Multiple Sclerosis

    Participants use of healthcare resources, non-medical resources, and informal care as well as their work capacity was assessed at scheduled study visits using a modified questionnaire (HRPQ) designed to evaluate the economic impact of MS. The questionnaire addresses the following content area: participant reported data regarding employment status, work productivity, impact on household chores due to MS. Data for "total scheduled working hours of participants; number of hours missed from work by participants due to MS" were reported in this outcome measure.

    Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60

  18. HRPQ: Percentage Impact on Work Output Due to Multiple Sclerosis

    Participants use of healthcare resources, non-medical resources, and informal care as well as their work capacity was assessed at scheduled study visits using a modified questionnaire (HRPQ) designed to evaluate the economic impact of MS. The questionnaire addresses the following content area: participant reported data regarding employment status, work productivity, impact on household chores due to MS. Percentage impact on work output due to MS were reported in this outcome measure.

    Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60

  19. HRPQ: Total Scheduled Household Chores Hours; Number of Hours Missed From Household Chores Due to Multiple Sclerosis

    Participants use of healthcare resources, non-medical resources, and informal care as well as their work capacity was assessed at scheduled study visits using a modified questionnaire (HRPQ) designed to evaluate the economic impact of MS. The questionnaire addresses the following content area: participant reported data regarding employment status, work productivity, impact on household chores due to MS. Data for "total scheduled household chores hours; number of hours missed from planned household chores by participants due to MS" were reported in this outcome measure.

    Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60

  20. HRPQ: Percentage Impact on Work Output for Household Chores Due to Multiple Sclerosis

    Participants use of healthcare resources, non-medical resources, and informal care as well as their work capacity was assessed at scheduled study visits using a modified questionnaire (HRPQ) designed to evaluate the economic impact of MS. The questionnaire addresses the following content area: participant reported data regarding employment status, work productivity, impact on household chores due to MS. Percentage impact on work output for household chores due to MS were reported in this outcome measure.

    Measured: Baseline (Month 0 of LPS13649), Month 12, Month 24, Month 36, Month 48 and Month 60

  21. HRPQ: Duration of Disease (in Months) Since Development of Multiple Sclerosis

    Participants use of healthcare resources, non-medical resources, and informal care as well as their work capacity was assessed at scheduled study visits using a modified questionnaire (HRPQ) designed to evaluate the economic impact of MS. The questionnaire addresses the following content area: participant reported data regarding employment status, work productivity, impact on household chores due to MS. Mean and standard deviation data for duration of MS disease (in months) since the start of MS development in participants was reported in this outcome measure.

    Measured: Baseline up to end of the study (up to a maximum duration of 5.6 years)

  22. HRPQ: Number of Participants Who Reported Impact on Work Due to Multiple Sclerosis

    Participants use of healthcare resources, non-medical resources, and informal care as well as their work capacity was assessed at scheduled study visits using a modified questionnaire (HRPQ) designed to evaluate the economic impact of MS. The questionnaire addresses the following content area: participant reported data regarding employment status, work productivity, impact on household chores due to MS. Number of participants who reported "Yes" as an answer to questions related to impact on work: "forced me to work part-time when I wanted to work full-time; kept me from having a job when I wanted to work full-time; kept me from having a job when I wanted to work part-time; none of the above" questions were reported in this outcome measure.

    Measured: Baseline up to end of the study (up to a maximum duration of 5.6 years)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Oct 2014 (estimated)
  2. Study start7 Jan 2015
  3. Primary completion15 Jul 2020
  4. Study completion15 Jul 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
1,062 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02255656
Sponsor's protocol ID
LPS13649
Other IDs
2013-003884-71, U1111-1148-2987
Acronym
TOPAZ
Status last verified
Mar 2022
First submitted
30 Sep 2014
Last updated
28 Mar 2022
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Publications

  • Ziemssen T, Bass AD, Van Wijmeersch B, Eichau S, Richter S, Hoffmann F, Armstrong NM, Chirieac M, Cunha-Santos J, Singer BA. Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study. Ther Adv Neurol Disord. 2025 Feb 10;18:17562864241306575. doi: 10.1177/17562864241306575. eCollection 2025.

    PubMed 39935588
  • Coles AJ, Achiron A, Traboulsee A, Singer BA, Pozzilli C, Oreja-Guevara C, Giovannoni G, Comi G, Freedman MS, Ziemssen T, Shiota D, Rawlings AM, Wong AT, Chirieac M, Montalban X. Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study. Ther Adv Neurol Disord. 2023 Sep 21;16:17562864231194823. doi: 10.1177/17562864231194823. eCollection 2023.

    PubMed 37745914
  • Coles AJ, Jones JL, Vermersch P, Traboulsee A, Bass AD, Boster A, Chan A, Comi G, Fernandez O, Giovannoni G, Kubala Havrdova E, LaGanke C, Montalban X, Oreja-Guevara C, Piehl F, Wiendl H, Ziemssen T. Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. Mult Scler. 2022 Apr;28(5):842-846. doi: 10.1177/13524585211061335. Epub 2021 Dec 9.

    PubMed 34882037
  • Kuhle J, Daizadeh N, Benkert P, Maceski A, Barro C, Michalak Z, Sormani MP, Godin J, Shankara S, Samad TA, Jacobs A, Chung L, Rӧsch N, Kaiser C, Mitchell CP, Leppert D, Havari E, Kappos L. Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS. Mult Scler. 2022 Apr;28(4):573-582. doi: 10.1177/13524585211032348. Epub 2021 Aug 11.

    PubMed 34378446
  • Bass AD, Arroyo R, Boster AL, Boyko AN, Eichau S, Ionete C, Limmroth V, Navas C, Pelletier D, Pozzilli C, Ravenscroft J, Sousa L, Tintore M, Uitdehaag BMJ, Baker DP, Daizadeh N, Choudhry Z, Rog D; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators. Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years. Mult Scler Relat Disord. 2021 Apr;49:102717. doi: 10.1016/j.msard.2020.102717. Epub 2020 Dec 24.

    PubMed 33476880
  • Ziemssen T, Bass AD, Berkovich R, Comi G, Eichau S, Hobart J, Hunter SF, LaGanke C, Limmroth V, Pelletier D, Pozzilli C, Schippling S, Sousa L, Traboulsee A, Uitdehaag BMJ, Van Wijmeersch B, Choudhry Z, Daizadeh N, Singer BA; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators. Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study. CNS Drugs. 2020 Sep;34(9):973-988. doi: 10.1007/s40263-020-00749-x.

    PubMed 32710396
  • Steingo B, Al Malik Y, Bass AD, Berkovich R, Carraro M, Fernandez O, Ionete C, Massacesi L, Meuth SG, Mitsikostas DD, Pardo G, Simm RF, Traboulsee A, Choudhry Z, Daizadeh N, Compston DAS; CAMMS223, CAMMS03409, and TOPAZ Investigators. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. J Neurol. 2020 Nov;267(11):3343-3353. doi: 10.1007/s00415-020-09983-1. Epub 2020 Jun 24.

    PubMed 32583052
  • Comi G, Alroughani R, Boster AL, Bass AD, Berkovich R, Fernandez O, Kim HJ, Limmroth V, Lycke J, Macdonell RA, Sharrack B, Singer BA, Vermersch P, Wiendl H, Ziemssen T, Jacobs A, Daizadeh N, Rodriguez CE, Traboulsee A; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators. Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies. Mult Scler. 2020 Dec;26(14):1866-1876. doi: 10.1177/1352458519888610. Epub 2019 Nov 25.

    PubMed 31762387
  • Okai AF, Amezcua L, Berkovich RR, Chinea AR, Edwards KR, Steingo B, Walker A, Jacobs AK, Daizadeh N, Williams MJ; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators. Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study). Neurol Ther. 2019 Dec;8(2):367-381. doi: 10.1007/s40120-019-00159-2. Epub 2019 Oct 25.

    PubMed 31654272

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing alemtuzumab GZ402673 in people with Relapsing Remitting Multiple Sclerosis, run by Genzyme, a Sanofi Company at 131 sites in 19 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 131 sites in United States, Russia, Australia, Germany, Canada and 14 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 23 Jul 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs) (time frame: From Baseline until the end of the study (up to a maximum duration of 5.6 years)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02255656, which also lists 9 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Mar 2022.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in